

COMPANY OVERVIEW

BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx[®] Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one proprietary counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. Additionally, we have expanded the support structure to include 12 months of a peer-support system utilizing trained recovery specialists. The company is also developing a patent pending injectable form of naltrexone.

RECENT NEWS

[BioCorRx Provides Business Update for the Third Quarter of 2018](#)

Nov 14 2018, 8:00 AM EST

[BioCorRx Inc.'s CEO Talks NIDA Grant Update and a Promising New Product with Uptick Newswire's Stock Day Podcast](#)

Oct 23 2018, 9:47 AM EDT

[BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families](#)

Oct 19 2018, 7:30 AM EDT

STOCK OVERVIEW

Symbol	BICX
Exchange	OTCQB
Market Cap	17.73m
Last Price	\$0.07
52-Week Range	\$0.041 - \$0.282

12/14/2018 02:05 PM EST

INVESTOR RELATIONS

Crescendo Communications, LLC
T: 212-671-1020 x304
bicx@crescendo-ir.com
investors@biocorr.com

MANAGEMENT TEAM

Brady Granier

President, CEO and Director

Lourdes Felix

CFO, COO and Director

Tom Welch

VP of Operations

Dr. David Gastfriend

Medical Consultant

Dr. George Fallieras

Medical Consultant

BIOCORRX, INC.

2390 E. Orangewood Ave.
Suite 575
Anaheim, CA 92806

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.